Developer docs
API playgroundTry for free, no card

Search company profiles

NRx Pharmaceuticals

Full company profile

uuid00002o5

Namestring
NRx Pharmaceuticals
Legal namestring
NRx Pharmaceuticals, Inc.
Websiteurl
nrxpharma.com
Company typeenum
Public
Founded yearint
2020
Descriptiontext

NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company developing NMDA and 5-HT2A receptor-targeting therapeutics for central nervous system disorders, with a primary focus on treatment-resistant depression, bipolar depression with suicidality, PTSD, and chronic pain. The company's core pipeline comprises NRX-100 (preservative-free intravenous ketamine targeting acute suicidal ideation), NRX-101 (a fixed-dose combination of D-cycloserine and lurasidone positioned as the first oral medication in FDA trials for suicidal bipolar depression), and KETAFREE (preservative-free IV ketamine pending ANDA approval with a July 29, 2026 GDUFA goal date). The company has accumulated four FDA regulatory designations (Fast Track for NRX-100, Breakthrough Therapy, Special Protocol Agreement, and a Biomarker Letter of Support for NRX-101) and a granted Expanded Access Protocol for NRX-101 as TMS augmentation therapy. NRx differentiates through the absence of Benzethonium Chloride preservative, non-controlled-substance scheduling of NRX-101, and a non-hallucinogenic mechanism that avoids addiction and neurotoxicity risks of traditional NMDA inhibitors.

The company's go-to-market combines pharmaceutical commercialization with direct clinical operations via its wholly-owned HOPE Therapeutics subsidiary, which operates a network of interventional psychiatry clinics in Florida offering TMS, ketamine therapies, and one-day depression protocols. Revenue generation began in Q3 2025 at approximately $240,000 from the clinic network and is scaling toward a multi-million dollar run-rate as the network expands from 5 to 8+ Florida locations through acquisitions (Dura Medical, Neurospa TMS, Cohen & Associates). The company has integrated third-party AI capabilities, including Zeta Surgical's FDA-cleared AI-guided TMS Navigation System and Emobot's EMOCARE Depression Thermometer, into the clinical workflow, and incorporated a separate NRx Defense Systems subsidiary in 2026 to pursue military, veteran, and first responder applications. NRx operates as a public company formed through a December 2020 SPAC merger with Big Rock Partners Acquisition Corp., with headquarters in Wilmington, Delaware, 11-50 employees, and a management team and board featuring former executives from Allergan, J&J, Lilly, Novartis, Pfizer, FDA, Teva, and DARPA.

Short descriptiontext

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing NMDA-targeting therapeutics (NRX-100, NRX-101, KETAFREE) for suicidal bipolar depression and treatment-resistant depression, supplemented by a wholly-owned Florida clinic network (HOPE Therapeutics) offering TMS and ketamine therapies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWilmington, United States
HQ citystring
Wilmington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CNS therapeutics, preservative-free ketamine, bipolar depression treatment, interventional psychiatry services, suicidal ideation drugs
Industry4 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
CNS Pharmaceuticals
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from sales of FDA-approved pharmaceutical products including preservative-free ketamine (NRX-100/NRX-101) and other CNS treatments. The company is preparing for commercial launch with anticipated approval of ANDA for KETAFREE in Summer 2026 and NDA for NRX-100 for suicidal ideation.

globenewswire.com
2Interventional Psychiatry Clinic Services
TypeSubscription Recurring
Description

Revenue generated from HOPE Therapeutics subsidiary operating interventional psychiatry clinics offering TMS treatments, ketamine therapies, and one-day depression treatment protocols. The company has opened five Florida clinic locations and completed acquisition of Dura Medical, Neurospa TMS, and Cohen & Associates, with coverage at more than 8 locations along Florida's West Coast.

citybiz.co
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1HOPE Therapeutics
Description

Subsidiary operating a network of interventional psychiatry clinics providing TMS and other treatments for depression and suicidality

in.investing.com
+4 more records
Core offering1 text field

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing NMDA-receptor-targeting therapeutics for central nervous system disorders, primarily suicidal bipolar depression, treatment-resistant depression, and PTSD. Its lead candidates are NRX-100 (preservative-free IV ketamine) and NRX-101 (D-cycloserine/lurasidone combination). The company also operates HOPE Therapeutics, a subsidiary running interventional psychiatry clinics in Florida offering TMS, ketamine, and AI-guided combination therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 34% remission rate with IV ketamine vs 26% with intranasal esketamine; 63% response rate vs 58%; IV ketamine patients approximately 50% more likely to achieve remission (OR 1.51, P<.001)
+4 more records
Product overview1 text field

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of NMDA-based therapeutics for central nervous system disorders, with its core products being NRX-100 (preservative-free IV ketamine) for acute suicidal ideation and NRX-101 (D-cycloserine/lurasidone combination) for bipolar depression with suicidality. The company operates through its HOPE Therapeutics subsidiary, a network of interventional psychiatry clinics offering TMS and ketamine treatments augmented by AI-powered monitoring tools. The pipeline is advancing through parallel FDA pathways with ANDA for KETAFREE and NDA for NRX-100, supported by real-world evidence from over 70,000 ketamine patients.

Product and service6 records
1NRX-100 (Preservative-Free IV Ketamine)
CategoryCNS Pharmaceuticals - Acute Suicidality Treatment
Description

Investigational preservative-free intravenous ketamine formulation (free of Benzethonium Chloride) for treating suicidal ideation in patients with depression and bipolar depression. Designed as the first FDA-approved medicine specifically for suicidal ideation beyond Electroconvulsive Therapy. Has received FDA Fast Track designation and is in development with a planned NDA submission.

2NRX-101 (D-cycloserine/Lurasidone Combination)
CategoryCNS Pharmaceuticals - Bipolar Depression Maintenance Therapy
Description

Fixed-dose combination of D-cycloserine (partial NMDA antagonist) and lurasidone (5-HT2A antagonist) for treating bipolar depression with suicidality. Being developed as adjunctive therapy with TMS for treatment-resistant depression. First oral medication in FDA trials for suicidal bipolar depression and not classified as a controlled substance by the DEA. Holds FDA Breakthrough Therapy Designation, Special Protocol Agreement, and Biomarker Letter of Support.

3KETAFREE (Preservative-Free IV Ketamine ANDA)
CategoryCNS Pharmaceuticals - Generic Ketamine
Description

Preservative-free IV ketamine product under FDA review via Abbreviated New Drug Application (ANDA). Would be the first preservative-free ketamine formulation in a market estimated at $750 million per year. FDA accepted the ANDA with GDUFA goal date of July 29, 2026.

4HOPE Therapeutics Clinic Services
CategoryInterventional Psychiatry Clinic Services
Description

Wholly-owned subsidiary operating a network of interventional psychiatry clinics in Florida offering TMS, ketamine treatments, one-day depression treatment protocols, and AI-guided TMS therapies directly to patients with treatment-resistant depression, bipolar depression, PTSD, and chronic pain. Expanded to five Florida locations including West Palm Beach, Sarasota, Naples, and Fort Myers.

5AI-Guided TMS Treatments at HOPE Clinics
CategoryInterventional Psychiatry Clinic Services
Description

Transcranial Magnetic Stimulation treatments using Zeta Surgical's FDA-cleared AI-powered Zeta TMS Navigation System, providing sub-millimetric image guidance accuracy. Reduces TMS setup times to under two minutes without conventional fiducial markers. Available at HOPE Therapeutics clinics in Florida.

6ONE-D Depression Treatment Protocol
CategoryInterventional Psychiatry Clinic Services
Description

One-day depression treatment protocol combining FDA-cleared Ampa device TMS with D-cycloserine and lisdexamfetamine, designed to achieve remission in single-day therapy for treatment-resistant depression patients. Offered at HOPE Therapeutics clinic locations.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-27
Description

Strategic partnership deploying Zeta Surgical's FDA-cleared AI-powered Zeta TMS Navigation System at HOPE Therapeutics clinics. HOPE became first commercial site to deploy the technology, using sub-millimetric image guidance for transcranial magnetic stimulation. Partnership supports planned SPARC-TMS clinical trial combining NRX-101 with robotic-enabled TMS.

2NRx Defense Systems
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-15
Description

Newly incorporated R&D subsidiary focused on developing robotic-enabled TMS combined with neuroplastic therapy for military and first responder applications. Led by Dr. Dennis McBride (former DARPA program manager and Navy Captain), partnering with Zeta Surgical to address five-fold increased risk of depression and PTSD in front-line troops.

in.investing.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-30
Description

Strategic partnership deploying Emobot's EMOCARE AI-powered Depression Thermometer across HOPE Therapeutics clinic network. The smartphone-based passive monitoring platform achieves 90% concordance with clinician assessments and helps detect early relapse to improve treatment outcomes.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-14
Description

Licensed real-world evidence data from over 70,000 patients treated with ketamine for depression and suicidal ideation, including nearly 1 million treatment sessions and hundreds of millions of datapoints, to support FDA accelerated approval of NRX-100 under Fast Track designation.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-02
Description

Historical partnership for global commercialization of ZYESAMI (aviptadil) for COVID-19 respiratory failure. Company has since focused on CNS disorders following ZYESAMI trial failures. Ongoing litigation with Relief regarding contract disputes.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-17
Description

Strategic partnership for neuroplastic treatment clinics, supporting the expansion of interventional psychiatry clinic network for depression and PTSD treatment.

7Ampa Health
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-11
Description

Partnership deploying first-in-Florida ONE-D protocol for treatment-resistant depression combining FDA-cleared Ampa device TMS with D-cyloserine and lisdexamfetamine, aiming to achieve remission in single-day therapy at multiple HOPE clinic locations.

biospace.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-08
Description

Completed acquisition of Dura Medical, a provider of interventional psychiatry services in Florida operating locations in Naples and Fort Myers. Revenue-generating and EBITDA positive. Founder Stephen Durand (US Army Veteran) appointed as Director of Florida Clinic Operations. Part of HOPE Therapeutics network expansion to 8+ locations.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-08
Description

Pending acquisitions to expand HOPE Therapeutics clinic network to more than 8 locations along Florida's West Coast, complementing existing Dura Medical locations.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
1Johnson & Johnson (Janssen)
TypeDirect peer
Description

Markets SPRAVATO (esketamine), the only FDA-approved ketamine-derived therapy for treatment-resistant depression. Directly competes with NRX-100/KETAFREE in the depression/suicidality space with established commercial infrastructure and payer coverage.

TypeDirect peer
Description

Develops CNS therapeutics including ZURZUVAE (zuranolone) for postpartum depression. Comparable clinical-stage CNS biopharmaceutical company with similar regulatory and commercial challenges in depression treatment market.

TypeDirect peer
Description

Develops Auvelity (dextromethorphan/bupropion) for major depressive disorder. Direct competitor in CNS depression therapeutics with overlapping mechanism (NMDA receptor modulation) and similar small-cap public company profile.

4Atai Life Sciences
TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing psychedelic and NMDA-targeting therapies for depression and PTSD. Comparable pipeline focus on treatment-resistant depression and suicidality, with similar regulatory pathway through FDA.

TypeEmerging player
Description

Pioneering psilocybin therapy for treatment-resistant depression. Comparable CNS-focused clinical-stage company targeting similar patient populations, with overlapping regulatory pathway and benefit from psychedelic medicine policy tailwinds.

6Mind Medicine (MindMed)
TypeEmerging player
Description

Clinical-stage CNS company developing psychedelic-inspired therapies including LSD-based treatments for anxiety and depression. Similar clinical-stage CNS profile, target indications, and regulatory pathway as NRx.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing mebufotenin (5-HT2A agonist) therapies for treatment-resistant depression. Overlapping mechanism (5-HT2A modulation) and similar target patient population with bipolar depression/suicidality.

TypeBroad incumbent
Description

Major pharmaceutical company with established CNS franchise including antidepressant portfolio and active NMDA/glutamate research programs. Represents broader competitive threat and potential acquirer of NMDA-targeting assets.

TypeDirect peer
Description

Pending acquisition target of NRx that operates interventional psychiatry clinics in Florida offering TMS treatments for depression. Directly comparable clinic operations being integrated into HOPE Therapeutics network.

TypeOthers
Description

Neuropsychiatry technology and medical records platform from which NRx licenses real-world evidence data on 70,000+ ketamine patients. Ecosystem partner providing data infrastructure rather than direct competitive threat.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NRx Pharmaceuticals

CNS Pharmaceuticalsnrxpharma.com

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing NMDA-targeting therapeutics (NRX-100, NRX-101, KETAFREE) for suicidal bipolar depression and treatment-resistant depression, supplemented by a wholly-owned Florida clinic network (HOPE Therapeutics) offering TMS and ketamine therapies.

What NRx Pharmaceuticals does

NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company developing NMDA and 5-HT2A receptor-targeting therapeutics for central nervous system disorders, with a primary focus on treatment-resistant depression, bipolar depression with suicidality, PTSD, and chronic pain. The company's core pipeline comprises NRX-100 (preservative-free intravenous ketamine targeting acute suicidal ideation), NRX-101 (a fixed-dose combination of D-cycloserine and lurasidone positioned as the first oral medication in FDA trials for suicidal bipolar depression), and KETAFREE (preservative-free IV ketamine pending ANDA approval with a July 29, 2026 GDUFA goal date). The company has accumulated four FDA regulatory designations (Fast Track for NRX-100, Breakthrough Therapy, Special Protocol Agreement, and a Biomarker Letter of Support for NRX-101) and a granted Expanded Access Protocol for NRX-101 as TMS augmentation therapy. NRx differentiates through the absence of Benzethonium Chloride preservative, non-controlled-substance scheduling of NRX-101, and a non-hallucinogenic mechanism that avoids addiction and neurotoxicity risks of traditional NMDA inhibitors.

The company's go-to-market combines pharmaceutical commercialization with direct clinical operations via its wholly-owned HOPE Therapeutics subsidiary, which operates a network of interventional psychiatry clinics in Florida offering TMS, ketamine therapies, and one-day depression protocols. Revenue generation began in Q3 2025 at approximately $240,000 from the clinic network and is scaling toward a multi-million dollar run-rate as the network expands from 5 to 8+ Florida locations through acquisitions (Dura Medical, Neurospa TMS, Cohen & Associates). The company has integrated third-party AI capabilities, including Zeta Surgical's FDA-cleared AI-guided TMS Navigation System and Emobot's EMOCARE Depression Thermometer, into the clinical workflow, and incorporated a separate NRx Defense Systems subsidiary in 2026 to pursue military, veteran, and first responder applications. NRx operates as a public company formed through a December 2020 SPAC merger with Big Rock Partners Acquisition Corp., with headquarters in Wilmington, Delaware, 11-50 employees, and a management team and board featuring former executives from Allergan, J&J, Lilly, Novartis, Pfizer, FDA, Teva, and DARPA.

NRx Pharmaceuticals firmographics

Firmographics
Name
NRx Pharmaceuticals
Legal name
NRx Pharmaceuticals, Inc.
Website
https://nrxpharma.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing NMDA-targeting therapeutics (NRX-100, NRX-101, KETAFREE) for suicidal bipolar depression and treatment-resistant depression, supplemented by a wholly-owned Florida clinic network (HOPE Therapeutics) offering TMS and ketamine therapies.
Ownership category
akta.pro rank

NRx Pharmaceuticals industry classification

Industry
Product category
CNS Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays

Keywords

  • CNS therapeutics
  • Preservative-free ketamine
  • Bipolar depression treatment
  • Interventional psychiatry services
  • Suicidal ideation drugs

Where NRx Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Wilmington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NRx Pharmaceuticals business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Pharmaceutical Product Sales: Revenue from sales of FDA-approved pharmaceutical products including preservative-free ketamine (NRX-100/NRX-101) and other CNS treatments. The company is preparing for commercial launch with anticipated approval of ANDA for KETAFREE in Summer 2026 and NDA for NRX-100 for suicidal ideation.
  2. Interventional Psychiatry Clinic Services: Revenue generated from HOPE Therapeutics subsidiary operating interventional psychiatry clinics offering TMS treatments, ketamine therapies, and one-day depression treatment protocols. The company has opened five Florida clinic locations and completed acquisition of Dura Medical, Neurospa TMS, and Cohen & Associates, with coverage at more than 8 locations along Florida's West Coast.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

NRx Pharmaceuticals product offering

Product offering

Core offering

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing NMDA-receptor-targeting therapeutics for central nervous system disorders, primarily suicidal bipolar depression, treatment-resistant depression, and PTSD. Its lead candidates are NRX-100 (preservative-free IV ketamine) and NRX-101 (D-cycloserine/lurasidone combination). The company also operates HOPE Therapeutics, a subsidiary running interventional psychiatry clinics in Florida offering TMS, ketamine, and AI-guided combination therapies.

Product overview

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of NMDA-based therapeutics for central nervous system disorders, with its core products being NRX-100 (preservative-free IV ketamine) for acute suicidal ideation and NRX-101 (D-cycloserine/lurasidone combination) for bipolar depression with suicidality. The company operates through its HOPE Therapeutics subsidiary, a network of interventional psychiatry clinics offering TMS and ketamine treatments augmented by AI-powered monitoring tools. The pipeline is advancing through parallel FDA pathways with ANDA for KETAFREE and NDA for NRX-100, supported by real-world evidence from over 70,000 ketamine patients.

Differentiator

Problem solved

Functional benefit

Brands

  • HOPE Therapeutics: Subsidiary operating a network of interventional psychiatry clinics providing TMS and other treatments for depression and suicidality
  • NRx Defense Systems
  • KETAFREE
  • ZYESAMI
  • BriLife

Products and services

  • NRX-100 (Preservative-Free IV Ketamine) Investigational preservative-free intravenous ketamine formulation (free of Benzethonium Chloride) for treating suicidal ideation in patients with depression and bipolar depression. Designed as the first FDA-approved medicine specifically for suicidal ideation beyond Electroconvulsive Therapy. Has received FDA Fast Track designation and is in development with a planned NDA submission.
  • NRX-101 (D-cycloserine/Lurasidone Combination) Fixed-dose combination of D-cycloserine (partial NMDA antagonist) and lurasidone (5-HT2A antagonist) for treating bipolar depression with suicidality. Being developed as adjunctive therapy with TMS for treatment-resistant depression. First oral medication in FDA trials for suicidal bipolar depression and not classified as a controlled substance by the DEA. Holds FDA Breakthrough Therapy Designation, Special Protocol Agreement, and Biomarker Letter of Support.
  • KETAFREE (Preservative-Free IV Ketamine ANDA) Preservative-free IV ketamine product under FDA review via Abbreviated New Drug Application (ANDA). Would be the first preservative-free ketamine formulation in a market estimated at $750 million per year. FDA accepted the ANDA with GDUFA goal date of July 29, 2026.
  • HOPE Therapeutics Clinic Services Wholly-owned subsidiary operating a network of interventional psychiatry clinics in Florida offering TMS, ketamine treatments, one-day depression treatment protocols, and AI-guided TMS therapies directly to patients with treatment-resistant depression, bipolar depression, PTSD, and chronic pain. Expanded to five Florida locations including West Palm Beach, Sarasota, Naples, and Fort Myers.
  • AI-Guided TMS Treatments at HOPE Clinics Transcranial Magnetic Stimulation treatments using Zeta Surgical's FDA-cleared AI-powered Zeta TMS Navigation System, providing sub-millimetric image guidance accuracy. Reduces TMS setup times to under two minutes without conventional fiducial markers. Available at HOPE Therapeutics clinics in Florida.
  • ONE-D Depression Treatment Protocol One-day depression treatment protocol combining FDA-cleared Ampa device TMS with D-cycloserine and lisdexamfetamine, designed to achieve remission in single-day therapy for treatment-resistant depression patients. Offered at HOPE Therapeutics clinic locations.

Quantifiable outcome

  • 34% remission rate with IV ketamine vs 26% with intranasal esketamine; 63% response rate vs 58%; IV ketamine patients approximately 50% more likely to achieve remission (OR 1.51, P<.001)
  • +4 more outcomes

Companies that use NRx Pharmaceuticals

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

NRx Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature4 records

NRx Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Zeta Surgical, Inc.coreTechnology or Integration · 27 May 2026Strategic partnership deploying Zeta Surgical's FDA-cleared AI-powered Zeta TMS Navigation System at HOPE Therapeutics clinics. HOPE became first commercial site to deploy the technology, using sub-millimetric image guidance for transcranial magnetic stimulation. Partnership supports planned SPARC-TMS clinical trial combining NRX-101 with robotic-enabled TMS.
  • NRx Defense SystemscoreStrategic or Co-development Partner · 15 April 2026Newly incorporated R&D subsidiary focused on developing robotic-enabled TMS combined with neuroplastic therapy for military and first responder applications. Led by Dr. Dennis McBride (former DARPA program manager and Navy Captain), partnering with Zeta Surgical to address five-fold increased risk of depression and PTSD in front-line troops.
  • Emobot HealthcoreTechnology or Integration · 30 March 2026Strategic partnership deploying Emobot's EMOCARE AI-powered Depression Thermometer across HOPE Therapeutics clinic network. The smartphone-based passive monitoring platform achieves 90% concordance with clinician assessments and helps detect early relapse to improve treatment outcomes.
  • Osmind, Inc.coreTechnology or Integration · 14 January 2026Licensed real-world evidence data from over 70,000 patients treated with ketamine for depression and suicidal ideation, including nearly 1 million treatment sessions and hundreds of millions of datapoints, to support FDA accelerated approval of NRX-100 under Fast Track designation.
  • Relief Therapeutics Holding AGminorStrategic or Co-development Partner · 2 December 2025Historical partnership for global commercialization of ZYESAMI (aviptadil) for COVID-19 respiratory failure. Company has since focused on CNS disorders following ZYESAMI trial failures. Ongoing litigation with Relief regarding contract disputes.
  • neurocare Group AGcoreStrategic or Co-development Partner · 17 November 2025Strategic partnership for neuroplastic treatment clinics, supporting the expansion of interventional psychiatry clinic network for depression and PTSD treatment.
  • Ampa HealthcoreStrategic or Co-development Partner · 11 November 2025Partnership deploying first-in-Florida ONE-D protocol for treatment-resistant depression combining FDA-cleared Ampa device TMS with D-cyloserine and lisdexamfetamine, aiming to achieve remission in single-day therapy at multiple HOPE clinic locations.
  • Dura MedicalcoreChannel Partner/ Reseller/ Distributor · 8 September 2025Completed acquisition of Dura Medical, a provider of interventional psychiatry services in Florida operating locations in Naples and Fort Myers. Revenue-generating and EBITDA positive. Founder Stephen Durand (US Army Veteran) appointed as Director of Florida Clinic Operations. Part of HOPE Therapeutics network expansion to 8+ locations.
  • Neurospa TMS and Cohen & AssociatescoreChannel Partner/ Reseller/ Distributor · 8 September 2025Pending acquisitions to expand HOPE Therapeutics clinic network to more than 8 locations along Florida's West Coast, complementing existing Dura Medical locations.

Scale indicators11 records

Recent moves6 records

Expansion highlights8 records

NRx Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Johnson & Johnson (Janssen): Markets SPRAVATO (esketamine), the only FDA-approved ketamine-derived therapy for treatment-resistant depression. Directly competes with NRX-100/KETAFREE in the depression/suicidality space with established commercial infrastructure and payer coverage.
  • Sage Therapeutics: Develops CNS therapeutics including ZURZUVAE (zuranolone) for postpartum depression. Comparable clinical-stage CNS biopharmaceutical company with similar regulatory and commercial challenges in depression treatment market.
  • Axsome Therapeutics: Develops Auvelity (dextromethorphan/bupropion) for major depressive disorder. Direct competitor in CNS depression therapeutics with overlapping mechanism (NMDA receptor modulation) and similar small-cap public company profile.
  • Neurospa TMS: Pending acquisition target of NRx that operates interventional psychiatry clinics in Florida offering TMS treatments for depression. Directly comparable clinic operations being integrated into HOPE Therapeutics network.

Emerging players

  • Atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and NMDA-targeting therapies for depression and PTSD. Comparable pipeline focus on treatment-resistant depression and suicidality, with similar regulatory pathway through FDA.
  • Compass Pathways: Pioneering psilocybin therapy for treatment-resistant depression. Comparable CNS-focused clinical-stage company targeting similar patient populations, with overlapping regulatory pathway and benefit from psychedelic medicine policy tailwinds.
  • Mind Medicine (MindMed): Clinical-stage CNS company developing psychedelic-inspired therapies including LSD-based treatments for anxiety and depression. Similar clinical-stage CNS profile, target indications, and regulatory pathway as NRx.
  • GH Research: Clinical-stage biopharmaceutical company developing mebufotenin (5-HT2A agonist) therapies for treatment-resistant depression. Overlapping mechanism (5-HT2A modulation) and similar target patient population with bipolar depression/suicidality.

Broad incumbents

  • Eli Lilly: Major pharmaceutical company with established CNS franchise including antidepressant portfolio and active NMDA/glutamate research programs. Represents broader competitive threat and potential acquirer of NMDA-targeting assets.

Others

  • Osmind: Neuropsychiatry technology and medical records platform from which NRx licenses real-world evidence data on 70,000+ ketamine patients. Ecosystem partner providing data infrastructure rather than direct competitive threat.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

NRx Pharmaceuticals social profiles

Digital presence

NRx Pharmaceuticals compliance and trust

Trust signal

Compliance7 records

NRx Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NRx Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles10 records

NRx Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

NRx Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NRx Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NRx Pharmaceuticals

What does NRx Pharmaceuticals do?

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing NMDA-receptor-targeting therapeutics for central nervous system disorders, primarily suicidal bipolar depression, treatment-resistant depression, and PTSD. Its lead candidates are NRX-100 (preservative-free IV ketamine) and NRX-101 (D-cycloserine/lurasidone combination). The company also operates HOPE Therapeutics, a subsidiary running interventional psychiatry clinics in Florida offering TMS, ketamine, and AI-guided combination therapies.

Is NRx Pharmaceuticals a public or private company?

NRx Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was NRx Pharmaceuticals founded?

NRx Pharmaceuticals was founded in 2020. It employs 11 to 50 people.

Where is NRx Pharmaceuticals based?

NRx Pharmaceuticals is headquartered in Wilmington, United States, in the North America region.

How does NRx Pharmaceuticals make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are interventional Psychiatry Clinic Services.

Who are NRx Pharmaceuticals's main competitors?

Direct peers on record are Johnson & Johnson (Janssen), Sage Therapeutics, Axsome Therapeutics and Neurospa TMS. Emerging players are Atai Life Sciences, Compass Pathways, Mind Medicine (MindMed) and GH Research. Eli Lilly is listed as a broad incumbent. Osmind is listed as an others.

Does NRx Pharmaceuticals have an API?

No public API is recorded for NRx Pharmaceuticals.

What industry is NRx Pharmaceuticals in?

NRx Pharmaceuticals's product category is CNS Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Motley FoolNRx (NRXP) Q3 2026 Earnings Call TranscriptNRx Pharmaceuticals reported Q3 2026 net loss of $2.2 million and net patient revenue of $1.2 million, following its first FDA approval of a preservative-free ketamine drug-device combination. The company also received a $11.2 million DARPA prime contract and has $19.8 million in cash, with a $400 million addressable market for sterile injectable ketamine.The Motley FoolNRx (NRXP) Q3 2026 Earnings Call TranscriptNRx Pharmaceuticals reported Q3 2026 net loss of $2.2 million and net patient revenue of $1.2 million, following its first FDA approval of a preservative-free ketamine drug-device combination. The company also received a $11.2 million DARPA prime contract and has $19.8 million in cash, with a $400 million addressable market for sterile injectable ketamine.Seeking AlphaNRx Pharmaceuticals, Inc. (NRXP) Q3 2026 Earnings Call TranscriptNRx Pharmaceuticals held its Q3 2026 earnings call on November 17, 2026, with CEO Jonathan Javitt and CFO Michael Abrams. The company filed its Form 10-Q for the quarter ended September 30, 2026, with the SEC. Javitt noted that the quarter saw seeds planted two years ago begin to take root.MarketWatchNRx Pharmaceuticals Shares Up on Narrower 3Q LossNRx Pharmaceuticals shares rose 9.8% to $2.36 after its third-quarter loss narrowed to $2.2 million, beating analyst expectations. Net patient service revenue nearly five-fold to $1.2 million, and the FDA approved its ketamine drug application in October.TradingViewNRx Pharmaceuticals, Inc. (NRXP) Q3 Revenue Rose to $1.2M; Net Loss Narrowed to $2.2MNRx Pharmaceuticals reported Q3 2026 net patient service revenue of $1.2 million, up from $0.2 million a year earlier, and a net loss of $2.2 million, down from $5.9 million. The company said FDA-approved preservative-free ketamine is commercially launching, with no product revenue reported.Simply Wall StNRx Pharmaceuticals (NRXP) Stock Looks Priced At A Premium Following Its 95% SlumpNRx Pharmaceuticals' stock trades at $2.15 after a 95% decline over five years. Its price-to-sales ratio of 27.4x is far above the sector's 4.1x and peers' 20.6x, flagging overvaluation. The stock's valuation hinges on converting its pipeline into sustainable revenue.FinancialContent Business PageCommercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, IncNRx Pharmaceuticals announced FDA approval of its preservative-free ketamine, which it began selling to address a long-running shortage. The company's sales force covers customers controlling about 80% of current U.S. ketamine sales, and Lucid Capital Markets issued a buy recommendation with a $49 price target.YahooNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate UpdateNRx Pharmaceuticals will report its third quarter 2026 financial results before market open on November 17, 2026, and host a conference call at 8:00am ET. The company also announced an $11.25 million contract from DARPA for a phase 3 trial of its oral drug NRX-101.Defense WorldNRx Pharmaceuticals (NASDAQ:NRXP) versus TherapeuticsMD (NASDAQ:TXMD) Head-To-Head ContrastNRx Pharmaceuticals and TherapeuticsMD are compared on institutional ownership, volatility, analyst ratings, and valuation. NRx has a consensus price target of $34.50, implying 1,419.82% upside, while TherapeuticsMD has a lower rating. NRx beats TherapeuticsMD on 8 of 14 factors.FinancialContent Business PageFDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, IncNRx Pharmaceuticals announced FDA approval of its preservative-free ketamine ANDA ahead of the November 10 goal date. The company also received an $11 million DARPA contract for a robotic magnetic stimulation trial. It completed process validation and two-year stability data for the ketamine.